MedCity News

OCTOBER 3, 2024

The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority.

Medical 321

Medical Healthcare Healthcare Patients 321

MedCity News

AUGUST 21, 2024

Lifestyle is equally important for long-term success. A good behavior-change program can benefit many people with chronic conditions – whether by impacting clinical outcomes, improving quality of life, or helping to lower long-term health-care costs.

Pharmaceutical 306

Pharmaceutical Physicians Biopharma Pharma 306

MedCity News

SEPTEMBER 15, 2024

To realize true, sustainable savings in total cost of care, the healthcare system needs to reconsider the support — or lack of support — it provides throughout patients’ medication experiences and the snowball effect that creates on a lifetime of healthcare costs.

Medical 295

Medical Healthcare Healthcare Patients 295

PM360

APRIL 22, 2024

From important changes to engaging physicians to finding out how new technologies will help address HCPs education needs, hear what our specialist had to say. What do you think are the most important changes to engaging physicians our industry needs to keep in mind now?

Education 59

Education Physicians Healthcare Healthcare 59

MedCity News

SEPTEMBER 18, 2024

While fibrates are proven to lower triglyceride levels, which can serve as a biomarker for cardiovascular disease risk, several major clinical studies from the past 20 years have failed to show a benefit of fenofibrates over and above statins in further reducing heart-related events.

FDA 299

FDA Physicians Biopharma Pharma 299

MedCity News

DECEMBER 15, 2024

How top-to-bottom collaboration can alleviate hurdles and help increase equitable access to the most effective treatments for all cancer patients. The post Closing the Gap: Advancing Precision Oncology Through Education and Collaboration appeared first on MedCity News.

Education 290

Education Patients Medicine Physicians 290

Clarify Health

MAY 19, 2020

There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. Which physicians see these patients? sales, medical science liaisons, etc.).

Biopharma 52

Biopharma Physicians Marketing Patients 52

Eversana Intouch

FEBRUARY 23, 2023

Let’s talk about the current economic uncertainty and what it means for pharma marketers. Biopharma valuations are down, especially for public and earlier-stage companies. What does this mean for pharma marketers? What’s the current situation? Pharmaceutical marketing: Increased utilization of financial support services.

Marketing 52

Marketing Pharma Patients Insurance 52

Eversana Intouch

FEBRUARY 23, 2023

Let’s talk about the current economic uncertainty and what it means for pharma marketers. Biopharma valuations are down, especially for public and earlier-stage companies. What does this mean for pharma marketers? What’s the current situation? Pharmaceutical marketing: Increased utilization of financial support services.

Marketing 52

Marketing Pharma Patients Insurance 52

Prognos Health

FEBRUARY 1, 2022

Small and midsize pharma at a commercialization disadvantage. The consultant’s data shows that average peak sales for new products is 50% higher in Big Pharma than it is among smaller players. Download our ebook: How small and midsize pharma gain economies of scale with an end-to-end RWD solution. Rosenorn, P. Jacquet, D.

Consulting 52

Consulting Physicians Pharma Biopharma 52

Clarivate

APRIL 24, 2023

CVS then began affiliating with health systems across the country (like Cleveland Clinic ) for physician oversight of MinuteClinic’s staffed midlevel providers, just as Walgreens was rising as a formidable competitor in the convenient care space through its own walk-in clinics that it launched in fall 2006. Key acquisitions by U.S.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

pharmaphorum

JUNE 12, 2017

Biopharma companies must take into account a multitude of factors when considering physician prescribing behaviors, and need a more integrated "pull-through" strategy across their teams, from managed markets, to marketing, to field sales.

Marketing 52

Marketing Engineering Biopharma Prescription 52

PM360

MAY 21, 2024

In this issue, we take a closer look at the evolution of the Smart TV and the increase of streaming services and how they can benefit the pharma industry. Biopharma marketers are following their audiences and investment in this channel continues to increase. According to Nielsen, streaming accounts for 38% of viewership hours.

Media 105

Media Healthcare Healthcare Marketing 105

Clarivate

JULY 5, 2023

and European physicians across six specialties, and global pipeline analysis curated by experts to provide insights into the evolving landscape. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Pharmaceutical Representative Training

JANUARY 29, 2025

The approval of new biosimilars and the process of finding a place for them in the healthcare space will have its own set of challenges: Physician Trust: Biologics are more well-known and trusted by physicians who have been exposed to them for years. 4] References: 1.

Marketing 52

Marketing Healthcare Healthcare Physicians 52

Impetus Digital

AUGUST 10, 2023

Last but not least, for smaller biopharma companies especially, the high cost of organizing a single in-person advisory board can make ongoing insight-gathering difficult.

Pharmaceutical 95

Pharmaceutical Transportation Food Biopharma 95

PM360

JUNE 16, 2023

To find out, PM360 asked experts within patient groups, pharma companies, and other industry partners: What are the keys to building trusting and mutually beneficial partnerships? do rare disease patients and advocacy groups most value or need from pharma? So, what are the keys to working with these groups?

Patients 98

Patients Pharma Education Recruitment 98

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Marketing Physicians Biopharma 52

Clarivate

OCTOBER 25, 2023

Unlike in Part D, Part B drugs are physician administered and there is less certainty regarding which drugs will be tapped for negotiations (i.e., How the IRA could affect treatment choice While price negotiations are intended to lower Medicare costs, they also present a challenge to physician practice economics.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

MAY 24, 2023

However, because this is a genetic condition and there’s a definitive diagnosis, hopefully that means the process will be relatively straightforward for patients and physicians.” The Muscular Dystrophy Association and parents are very vocal and from the access side, there will be a push to accelerate that process as much as possible.”

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

Clarivate

MAY 24, 2022

Multinational pharmas seek entry for their products. Multinational pharmas have taken notice of the recent policy focus of Mainland China’s healthcare authorities on rare diseases. China’s rapidly evolving and increasingly dynamic rare disease market provides pharmas an opportunity for strong growth.

Patients 52

Patients Food and Drug Administration Marketing Pharma 52

PM360

AUGUST 7, 2024

Christoph Bug Vice President of Global Medical Veeva christoph.bug@veeva.com Functional silos can create tunnel vision and cause misalignment of strategy, objectives, and transparency of interactions with biopharmas and their customers like HCPs. To best align success measures and unify systems (and people) start with the end goal in mind.

Media 52

Media Education Physicians Marketing 52

Clarivate

JUNE 22, 2023

Questions such as where the patients are, and who and where the prescribing physicians are, can now be answered with pinpoint accuracy. The inclusion of advanced analytics enables RWD to go further than ever before, creating a complementary and robust data set that describes the market for a particular drug.

Patients 52

Patients Electronics Medical Distribution 52

PM360

JUNE 24, 2024

For example, a biopharma may want to track the improvement in patient adherence to a therapy pre- and post-launch of a PSP across regions to gauge its impact. On average, they’ve visited seven physicians before getting a diagnosis. Measuring the impact of PSPs is just as important to continue delivering the best outcome for patients.

Patients 118

Patients Education Healthcare Healthcare 118

Clarivate

DECEMBER 7, 2021

Black Americans are more likely to face barriers to care, including poor transportation options, a lack of local specialist physicians and inflexible work situations that make taking time off to seek care prohibitively difficult. A Clarivate survey of physicians found that at the pandemic’s outset, in the spring of 2020, 21% of U.S.

Healthcare 52

Healthcare Healthcare Transportation Physicians 52

Clarivate

OCTOBER 10, 2022

The biochemically recurrent treatment setting is heterogenous with no clear consensus on timing of hormonal therapy and duration of therapy among physicians. If approved, ERLEADA is likely to compete with Pfizer’s XTANDI®, which is also poised to enter this setting and may benefit from greater physician familiarity. Key ESMO findings.

Marketing 52

Marketing Safety Patients Competition 52

PM360

DECEMBER 14, 2023

Moderna Joins CEPI Pandemic Preparedness Mission After making its debut in the pharma market during the COVID-19 pandemic, Moderna is preparing for the next pandemic. The pharma company has joined the Coalition for Epidemic Preparedness Innovations (CEPI) in a partnership that aims to shorten vaccine development timelines down to 100 days.

Physicians 52

Physicians Pharma Medical Patients 52

Clarivate

DECEMBER 1, 2021

Treatment cost and compliance are key factors in sustaining effective long-term disease management, a powerful new oral option could be more widely accepted than the injectable competition and rapidly gain traction in the market, especially among primary care physicians.

Patients 52

Patients Safety Management Marketing 52

MedCity News

NOVEMBER 13, 2024

Bariatric surgery is still the gold standard for morbid obesity treatment, yet patients and medical professionals will likely seek less invasive weight loss drugs before considering bariatric surgery. The post The Rapid Growth of GLP-1s and Their Impact on Bariatric Surgery appeared first on MedCity News.

Medical 297

Medical Patients Pharmaceutical Physicians 297

Clarivate

AUGUST 20, 2024

In 2026, CMS will select up to 15 additional Part B or Part D drugs for negotiations that take effect in 2028, and up to 20 additional drugs every year thereafter (Part B covers physician-administered drugs, including infusions of complex biologics).

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Clarivate

OCTOBER 17, 2024

The Inflation Reduction Act instead allows the Centers for Medicare & Medicaid Services to begin negotiating Fair Maximum Prices for a growing list of Part D (outpatient) and Part B (physician-administered) drugs that represent the greatest cost to the federal government.

Healthcare 52

Healthcare Healthcare Government Insurance 52